Clinical and laboratory rationale for use of correctors of metabolism for treatment of patients with new coronavirus infection COVID-19 in acute period with background of cerebrovascular disease

Objective. The aim of the study was to evaluate the effectiveness of the drug Mildronate in the complex therapy of patients with a new coronavirus infection COVID-19 in the acute period and the background of cerebrovascular disease.

Material and methods. The material for the study was the medical records of 210 patients (140 women and 70 men) who had COVID-19 coronavirus infection against the background of cerebrovascular pathology in the period from 04.10.2020 to 12.31.2021. 120 patients (75 women and 45 men) received the drug Mildronate as part of complex therapy, 90 patients (55 women 35 men) made up the control group, received complex treatment without the use of the drug Mildronate. Patients in both groups were comparable in age, the average age was 76.5 years (from 50 to 93 years). Groups according to nosological forms were distributed as follows: in the main group – ischemic stroke of various localization – 70 patients (48 women and 22 men), chronic cerebrovascular insufficiency of varying severity – 50 patients (27 women and 23 men); in the control group – ischemic stroke of various localization was in 50 patients (36 women and 14 men), chronic cerebrovascular insufficiency – 40 patients (19 women and 21 men). To correct chronic hypoxia, the drug Mildronate was chosen, which is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation under conditions of ischemia and hypoxia. Also, Mildronate is one of the universal cytoprotectors with a pronounced neuro-, cardio- and angioprotective effect, which goes well with drugs of other pharmacological groups.

Results. The drug Mildronate is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation in conditions of ischemia and hypoxia. According to the observations, it can be noted that the neurological status during mildronate therapy has a more significant regression trend with good rehabilitation potential – 56.0% of patients can serve themselves independently, while patients in the control group reached a level of 9 points only in 51.0% of cases. A significant neurological defect remained in the main group in 6.2% of patients, in the control group this figure was 8.8%.

1. Khalimov A., Orynbasar A., Yakupov B. Antioxidants in the fight against viruses. 2021. URL: https://kazatu.edu.kz/assets/i/science/sf16-matematika1–409.pdf (accessed 30.04.2022).

2. Akki R., Fath N., Mohti H. COVID-19: Oxidative Preconditioning as a Potential Therapeutic Approach. ACS Chemical Neuroscience. 2020. Vol. 11. No. 22. P. 3732–3740. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670822/

3. Crdenas-Rodrguez N., Bandala C., Vanoye-Carlo A. [et al.] Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. Antioxidants. 2021. Vol. 10. No. 6. P. 971. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235474/

4. Flieger J., Flieger W., Baj J., Maciejewski R. Antioxidants: Classification, Natural Sources, Activity/Capacity Measurements, and Usefulness for the Synthesis of Nanoparticles. Materials. 2021. Vol. 14. No. 15. P. 4135. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347950/

5. Vilskersts R., Kigitovica D., Korzh S. [et al.] Protective Effects of Meldonium in Experimental Models of Cardiovascular Complications with a Potential Application in COVID-19. International Journal of Molecular Sciences. 2022. Vol. 23. No. 1. P. 45. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744985/

6. Badalyan K.R., Solovieva E. Yu. Covid-19: long-term health consequences. Consilium Medicum. 2021. V. 23. No. 12. P. 993–999. URL: https://consilium.orscience.ru/2075–1753/article/view/100043/73554

7. Vertkin A.L., Shishkova V.N., Sycheva A.S., Kebina A.L., Nosova A.V., Uryanskaya K.A., Gazikova H.M. Possibilities of metabolic support in coronavirus infection. Therapy. 2020. No. 7 (41). P. 146–155. URL: https://mildronat.by/wp-content/uploads/2021/06/publication_3.pdf

8. Darenskaya M.A., Kolesnikova L.I., Kolesnikov S.I. Covid-19: oxidative stress and the relevance of antioxidant therapy. Bulletin of the Russian Academy of Medical Sciences. 2020. V. 75. No. 4. P. 318–325. URL: https://cyberleninka.ru/article/n/covid-19-okislitelnyy-stress-i-aktualnost-antioksidantnoy-terapii

9. Kovalchuk V.V. The role of a new coronavirus infection (covid-19) in the progression and development of cerebrovascular diseases. A competent choice of means in pathogenetic therapy is the key to success of treatment and prevention. View of a specialist from the ‘red zone’. Neurology, neuropsychiatry, psychosomatics. 2021. V. 13. No. 1. P. 57–66. URL: https://cyberleninka.ru/article/n/rol-novoy-koronavirusnoy-infektsii-covid-19-v-progressirovanii-i-razvitii-sosudistyh-zabolevaniy-golovnogo-mozga-gramotnyy-vybor

10. Privalova M.A., Sokolova M.G., Kabanov M. Yu., Zueva O.N., Bozhkov I.A., Lopatina E.V. Retrospective analysis of cerebral neurological complications against the background of seasonal respiratory viral infections and new coronavirus infection Covid-19. Medical Alphabet ‘Neurology and Psychiatry’ 2021. No. 36. Pp. 40–44. DOI: 10.33667/2078–5631–2021–36–47–51. https://www.elibrary.ru/item.asp?id=47417809

11. Potupchik T.V., Evert L.S., Kostyuchenko Yu.R. Influence of coronavirus infection on cognitive functions in elderly patients. Physician. 2021. V. 32. No. 6. P. 41–50. URL: http://belinkaluga.ru/public/covid/35.pdf

12. Putilina M.V., Teplova N.V., Gerasimova O.S. A differentiated approach to the treatment of cognitive disorders associated with SARS-CoV-2 (COVID19) taking into account the comorbidity factor. Medical Alphabet. 2021. No. 22. P. 18–24. URL: https://disk.yandex.ru/i/sBHgDE7fscL0Lg

13. Sokolova M.G., Privalova M.A., Shavurov V.A., Shtakelberg O. Yu., Lopatina E.V., Pasatetskaya N.A. Clinical and neurophysiological correlations in patients who underwent COVID-19 and the rationale for pathogenetic therapy. Medical Alphabet ‘Neurology and Psychiatry’. 2021. No. 36. Pp. 29–33. DOI: 10.33667/2078–5631–2021–36–7–11. https://www.elibrary.ru/item.asp?id=47417802

14. Statsenko M.E., Turkina S.V., Lopushkova Yu.E. New data on a well-known drug: focus on meldonium. Medical Council. 2021. No. 14. P. 110–117. URL: https://cyberleninka.ru/article/n/novye-dannye-o-horosho-izvestnom-preparate-fokusna-meldoniy

15. Shavarova E. K., Kazakhmedov E. R., Alekseeva M. V., Ezhova L. G., Kobalava Zh.D. The role of antioxidant therapy in patients with moderate and severe novel coronavirus infection COVID-19. Infectious Diseases. 2021. V. 19. No. 1. P. 159–165. URL: https://mexidol.ru/wp-content/uploads/2021_shavarova.pdf

16. Shishkova V.N., Sayutina E.V., Kapustina L.A., Osychenko M.E. Preliminary assessment of the relationship between the development of acute respiratory infections and Mildronate therapy in elderly patients. Practical Pulmonology. 2020. No. 1. P. 49–54. URL: https://cyberleninka.ru/article/n/predvaritelnaya-otsenka-vzaimosvyazi-razvitiya-ostryh-respiratornyh-infektsiy-i-terapii-mildronatom-u-pozhilyh-patsientov